BiDil | 682335-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃类
• 英文名称: BiDil
• 英文别名: [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate;phthalazin-1-ylhydrazine;hydrochloride
• CAS: 682335-44-0
• 化学式: C14H17ClN6O8
• 分子量: 432.77
• InChiKey: AVCYYEUQUXOUPI-SADXPQEKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.28
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  192
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• Methods for reducing hospitalizations related to heart failure
  申请人：Worcel Manuel

  公开号：US20060014829A1

  公开（公告）日：2006-01-19

  The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays; (e) reducing the number of hospital admissions for heart failure; and (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and/or the number of hospital visits) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.

  本发明提供了用于(a)延长心力衰竭住院时间的方法；(b)延长心力衰竭首次住院时间的方法；(c)减少心力衰竭患者因心力衰竭单次住院的总天数（即减少心力衰竭患者单次住院时间）的方法；(d)减少心力衰竭患者多次住院的总天数的方法；(e)减少心力衰竭患者入院次数的方法、(d) 减少心力衰竭患者因心力衰竭多次住院的总天数； (e) 减少因心力衰竭入院的次数；以及 (f) 降低死亡率，减少因心力衰竭住院的次数（例如，减少因心力衰竭住院的总天数）、(f) 降低有需要的患者的死亡率和减少因心力衰竭住院的次数（如住院总天数和/或住院次数），包括向患者施用治疗有效量的 (i) 氢拉嗪化合物或其药学上可接受的盐；(ii) 二硝酸异山梨酯和/或单硝酸异山梨酯、和 (iii) 可选的至少一种选自血管紧张素转换酶抑制剂、β-肾上腺素能拮抗剂、血管紧张素 II 拮抗剂、醛固酮拮抗剂、强心甙（洋地黄）和利尿化合物的化合物。
• Compositions and methods related to heart failure
  申请人：Worcel Manuel

  公开号：US20060014828A1

  公开（公告）日：2006-01-19

  The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); (e) reducing the number of hospital admissions for heart failure; (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and/or the number of hospital visits); (g) increasing the left ventricular ejection fraction in a heart failure patient; (h) treating a sexual dysfunction (e.g., erectile dysfunction and female sexual dysfunction) (j) treating a headache in a heart failure patient by administering a non-steroidal antiinflammatory compound (i.e., NSAIDs); (k) treating a heart failure patient who has a history of hypertension (but who is not currently diagnosed with hypertension); (l) improving the quality of life in a heart failure patient based on the Minnesota Living with heart failure questionnaire; (m) decreasing the levels of B-type natriuretic peptide; (n) treating hypertension in a heart failure patient; (o) lowering blood pressure in a heart failure patient; (p) treating labile hypertension; (q) treating idiopathic hypertension; (r) increasing patient compliance with medication dosing in a heart failure patient; (s) treating hypertension in a patient with a dilated heart; (t) treating ischemic disease and/or coronary artery disease; and (u) reducing cardiomegaly in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.

  本发明提供了以下方法：(a) 延长心力衰竭住院时间；(b) 延长心力衰竭首次住院时间；(c) 减少心力衰竭患者因心力衰竭单次住院的总天数（即减少心力衰竭患者单次住院时间）；(d) 减少心力衰竭患者因心力衰竭多次住院（即两次或多次住院）的总天数；(e) 减少心力衰竭入院次数；(f) 降低心力衰竭死亡率和减少心力衰竭住院次数（例如，减少心力衰竭住院次数）、(e) 减少因心力衰竭而入院的次数； (f) 降低死亡率，减少因心力衰竭而住院的次数（例如，因心力衰竭而住院的总天数）； (g) 减少因心力衰竭而住院的总天数； (h) 减少因心力衰竭而住院的总天数、(g) 增加心力衰竭患者的左心室射血分数； (h) 治疗性功能障碍（如勃起功能障碍和女性性功能障碍）； (i) 通过使用非甾体抗炎药物（即非甾体抗炎药）治疗心力衰竭患者的头痛； (j) 通过使用非甾体抗炎药物（即非甾体抗炎药）治疗心力衰竭患者的头痛； (k) 通过使用非甾体抗炎药物（即非甾体抗炎药）治疗心力衰竭患者的头痛； (l) 通过使用非甾体抗炎药物（即非甾体抗炎药）治疗心力衰竭患者的头痛、(k) 治疗有高血压病史（但目前未确诊为高血压）的心力衰竭患者； (l) 根据明尼苏达心力衰竭生活调查问卷，改善心力衰竭患者的生活质量； (m) 降低 B 型钠尿肽的水平；(n) 治疗心力衰竭患者的高血压； (o) 降低心力衰竭患者的血压； (p) 治疗易感性高血压； (q) 治疗特发性高血压； (r) 提高心力衰竭患者对药物剂量的依从性； (s) 治疗心脏扩张患者的高血压；(t) 治疗缺血性疾病和/或冠状动脉疾病；(u) 减轻有需要的患者的心脏肥大，包括向患者施用治疗有效量的 (i) 水拉嗪化合物或其药学上可接受的盐；(ii) 二硝酸异山梨酯和/或单硝酸异山梨酯、和 (iii) 可选的至少一种选自血管紧张素转换酶抑制剂、β-肾上腺素能拮抗剂、血管紧张素 II 拮抗剂、醛固酮拮抗剂、强心甙（洋地黄）和利尿化合物组成的组的化合物。
• COMPOSITIONS AND METHODS RELATED TO HEART FAILURE
  申请人：Nitromed, Inc.

  公开号：EP1778267A2

  公开（公告）日：2007-05-02
• SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE AND PAOD; METHODS OF TREATMENT
  申请人：Decode Genetics EHF.

  公开号：EP1871908A2

  公开（公告）日：2008-01-02
• Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
  申请人：Helgadottir Anna

  公开号：US20070280917A1

  公开（公告）日：2007-12-06

  Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.